CoChat

Distinct Mechanisms of Human Retinal Endothelial Barrier Modulation In Vitro by Mediators of Diabetes and Uveitis

Open access

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Abstract

Ocular diseases such as diabetic retinopathy (DR) and uveitis are associated with injury to the blood–retinal barrier (BRB). Whereas high glucose (HG) and advanced glycation end products (AGE) contribute to DR, bacterial infections causing uveitis are triggered by endotoxins such as lipopolysaccharide (LPS). It is unclear how HG, AGE, and LPS affect human retinal endothelial cell (HREC) junctions. Moreover, tumor necrosis factor-α (TNFα) is elevated in both DR and ocular infections. In the current study, we determined the direct effects of HG, AGE, TNFα, and LPS on the expression and intracellular distribution of claudin-5, VE-cadherin, and β-catenin in HRECs and how these mediators affect Akt and P38 MAP kinase that have been implicated in ocular pathologies. In our results, whereas HG, AGE, and TNFα activated both Akt and P38 MAPK, LPS treatment suppressed Akt but increased P38 MAPK phosphorylation. Furthermore, while treatment with AGE and HG increased cell-junction protein expression in HRECs, LPS elicited a paradoxical effect. By contrast, when HG treatment increased HREC-barrier resistance, AGE and LPS stimulation compromised it, and TNFα had no effect. Together, our results demonstrated the differential effects of the mediators of diabetes and infection on HREC-barrier modulation leading to BRB injury.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/life12010033

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 HG treatments in two different conditions differentially modulate Akt and P38 MAPK phosphorylation in HRECs. Two conditions of HG treatments (50–50 change every 24 h versus no change in media for (5 d) were performed in HREC monolayers. (A) Representative Western blot images of HREC lysates treated with two different conditions of HG (30 mM) showing changes in the expression of phosphorylated Akt and P38 MAP kinase compared to their respective controls. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt expression in HRECs treated with HG (50–50 (n = 6) versus no change (n = 14), (5 d) compared to respective untreated controls. (D,E) Bar graph showing band densitometry analysis of pThr308-Akt expression in HRECs treated with HG (50–50 versus (n = 3) no change (n = 3), (5 d) compared to respective untreated controls. (F,G) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with HG (50–50 (n = 6) versus no change (n = 16), (5 d) compared to respective untreated controls. Data are presented as Mean + SEM. * p < 0.05; # p < 0.001.
Figure 1 HG treatments in two different conditions differentially modulate Akt and P38 MAPK phosphorylation in HRECs. Two conditions of HG treatments (50–50 change every 24 h versus no change in media for (5 d) were performed in HREC monolayers. (A) Representative Western blot images of HREC lysates treated with two different conditions of HG (30 mM) showing changes in the expression of phosphorylated Akt and P38 MAP kinase compared to their respective controls. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt expression in HRECs treated with HG (50–50 (n = 6) versus no change (n = 14), (5 d) compared to respective untreated controls. (D,E) Bar graph showing band densitometry analysis of pThr308-Akt expression in HRECs treated with HG (50–50 versus (n = 3) no change (n = 3), (5 d) compared to respective untreated controls. (F,G) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with HG (50–50 (n = 6) versus no change (n = 16), (5 d) compared to respective untreated controls. Data are presented as Mean + SEM. * p < 0.05; # p < 0.001.CC BY · PubMed Central
Figure 2 HG treatments in two different conditions differentially modulate HREC-barrier protein expression in vitro. (A) Representative Western blot images of HREC lysates treated with two different conditions of HG (30 mM) for 5 d showing changes in the expression of AJ protein VE-cadherin and TJ protein CLDN5. (B,C) Bar graph showing band densitometry analysis of CLDN5 expression in HRECs treated with HG (50–50 (n = 4) versus no change (n = 15), (5 d) compared to respective untreated controls. (D,E) Bar graph showing band densitometry analysis of VE-cadherin expression in HRECs treated with HG (50–50 (n = 6) versus no change (n = 3), (5 d) compared to respective untreated controls. Data is presented as Mean + SEM. * p < 0.05.
Figure 2 HG treatments in two different conditions differentially modulate HREC-barrier protein expression in vitro. (A) Representative Western blot images of HREC lysates treated with two different conditions of HG (30 mM) for 5 d showing changes in the expression of AJ protein VE-cadherin and TJ protein CLDN5. (B,C) Bar graph showing band densitometry analysis of CLDN5 expression in HRECs treated with HG (50–50 (n = 4) versus no change (n = 15), (5 d) compared to respective untreated controls. (D,E) Bar graph showing band densitometry analysis of VE-cadherin expression in HRECs treated with HG (50–50 (n = 6) versus no change (n = 3), (5 d) compared to respective untreated controls. Data is presented as Mean + SEM. * p < 0.05.CC BY · PubMed Central
Figure 3 TNFα treatment of HRECs reduces CLDN5 and increases VE-cadherin expression. (A) Representative Western blot images of HREC lysates treated with TNFα (10 ng/mL) for 24 h showing changes in the expression of phosphorylated Akt and P38 MAP kinase, VE-cadherin, and CLDN5. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt (n = 5) and pThr308-Akt (n = 3) expression in HRECs treated with TNFα compared to untreated controls. (D) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with TNFα compared to untreated controls (n = 14). (E,F) Bar graph showing band densitometry analysis of CLDN5 (n = 12) and VE-cadherin (n = 8) expression in HRECs treated with TNFα compared to untreated controls. Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01.
Figure 3 TNFα treatment of HRECs reduces CLDN5 and increases VE-cadherin expression. (A) Representative Western blot images of HREC lysates treated with TNFα (10 ng/mL) for 24 h showing changes in the expression of phosphorylated Akt and P38 MAP kinase, VE-cadherin, and CLDN5. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt (n = 5) and pThr308-Akt (n = 3) expression in HRECs treated with TNFα compared to untreated controls. (D) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with TNFα compared to untreated controls (n = 14). (E,F) Bar graph showing band densitometry analysis of CLDN5 (n = 12) and VE-cadherin (n = 8) expression in HRECs treated with TNFα compared to untreated controls. Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01.CC BY · PubMed Central
Figure 4 Treatment with AGE activated Akt and P38 MAPK and increased VE-cadherin expression in HRECs. (A) Representative Western blot images of HREC lysates treated with AGE (25, 50, and 100 μg/mL) for 24 h show changes in phosphorylated Akt and P38 MAP kinase expression VE-cadherin, and CLDN5. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt (n = 6) and pThr308-Akt (n = 4) expression in HRECs treated with AGE compared to untreated controls. (D) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with AGE compared to untreated controls (n = 6). (E,F) Bar graph showing band densitometry analysis of CLDN5 (n = 5) and VE-cadherin (n = 4) expression in HRECs treated with AGE compared to untreated controls. Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01; # p < 0.001.
Figure 4 Treatment with AGE activated Akt and P38 MAPK and increased VE-cadherin expression in HRECs. (A) Representative Western blot images of HREC lysates treated with AGE (25, 50, and 100 μg/mL) for 24 h show changes in phosphorylated Akt and P38 MAP kinase expression VE-cadherin, and CLDN5. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt (n = 6) and pThr308-Akt (n = 4) expression in HRECs treated with AGE compared to untreated controls. (D) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with AGE compared to untreated controls (n = 6). (E,F) Bar graph showing band densitometry analysis of CLDN5 (n = 5) and VE-cadherin (n = 4) expression in HRECs treated with AGE compared to untreated controls. Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01; # p < 0.001.CC BY · PubMed Central
Figure 5 Treatment of HRECs with LPS reduced expression of CLDN5 but not VE-Cadherin. (A) Representative Western blot images of HREC lysates treated with LPS (0.1, 0.5, and 1 μg/mL) for 24 h showed changes in phosphorylated Akt and P38 MAP kinase expression VE-cadherin, and CLDN5. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt (n = 6) and pThr308-Akt (n = 3) expression in HRECs treated with LPS compared to untreated controls. (D) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with LPS compared to untreated controls (n = 5). (E,F) Bar graph showing band densitometry analysis of CLDN5 (n = 10) and VE-cadherin (n = 6) expression in HRECs treated with LPS compared to untreated controls. Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01; # p < 0.001.
Figure 5 Treatment of HRECs with LPS reduced expression of CLDN5 but not VE-Cadherin. (A) Representative Western blot images of HREC lysates treated with LPS (0.1, 0.5, and 1 μg/mL) for 24 h showed changes in phosphorylated Akt and P38 MAP kinase expression VE-cadherin, and CLDN5. (B,C) Bar graph showing band densitometry analysis of pSer473-Akt (n = 6) and pThr308-Akt (n = 3) expression in HRECs treated with LPS compared to untreated controls. (D) Bar graph showing band densitometry analysis of pP38 MAPK expression in HRECs treated with LPS compared to untreated controls (n = 5). (E,F) Bar graph showing band densitometry analysis of CLDN5 (n = 10) and VE-cadherin (n = 6) expression in HRECs treated with LPS compared to untreated controls. Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01; # p < 0.001.CC BY · PubMed Central
Figure 6 HG, AGE, LPS, and TNFα differentially modulated HREC-barrier resistance. (A) Graph showing real-time changes in HREC-barrier resistance after treatments with HG (30 mM), TNFα (10 ng/mL), and LPS (0.1 μg/mL) for 24 h compared to saline-treated control as measured using ECIS equipment (n = 4). (B) Graph showing real-time changes in HREC-barrier resistance after treatments with 50 μg/mL AGE and/or 10 μM TCBN for 24 h compared to saline-treated control as measured using ECIS equipment (n = 4). (C,D) Representative Western blot images and the densitometry analysis of HRECs treated with 50 μg/mL AGE and/or 10 μM TCBN (Akt inhibitor) for 24 h showing changes in pSer308Akt phosphorylation normalized to total Akt and GAPDH (n = 4). Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01; # p < 0.001.
Figure 6 HG, AGE, LPS, and TNFα differentially modulated HREC-barrier resistance. (A) Graph showing real-time changes in HREC-barrier resistance after treatments with HG (30 mM), TNFα (10 ng/mL), and LPS (0.1 μg/mL) for 24 h compared to saline-treated control as measured using ECIS equipment (n = 4). (B) Graph showing real-time changes in HREC-barrier resistance after treatments with 50 μg/mL AGE and/or 10 μM TCBN for 24 h compared to saline-treated control as measured using ECIS equipment (n = 4). (C,D) Representative Western blot images and the densitometry analysis of HRECs treated with 50 μg/mL AGE and/or 10 μM TCBN (Akt inhibitor) for 24 h showing changes in pSer308Akt phosphorylation normalized to total Akt and GAPDH (n = 4). Data are presented as Mean + SEM. * p < 0.05; ** p < 0.01; # p < 0.001.CC BY · PubMed Central
Figure 7 HG, AGE, LPS, and TNFα treatment resulted in different intracellular distribution of CLDN5 in HRECs. Representative confocal images of HREC monolayers subjected to 24 h treatment with TNFα (10 ng/mL), LPS (0.1 μg/mL), AGE (50 μg/mL), HG (30 mM), TCBN (10 μM), HG + TCBN, and AGE + TCBN showing changes in the intracellular distribution of CLDN5 compared to PBS control. Images were taken using an LSM confocal microscope at 63× magnification (Scale bars: 10 μM).
Figure 7 HG, AGE, LPS, and TNFα treatment resulted in different intracellular distribution of CLDN5 in HRECs. Representative confocal images of HREC monolayers subjected to 24 h treatment with TNFα (10 ng/mL), LPS (0.1 μg/mL), AGE (50 μg/mL), HG (30 mM), TCBN (10 μM), HG + TCBN, and AGE + TCBN showing changes in the intracellular distribution of CLDN5 compared to PBS control. Images were taken using an LSM confocal microscope at 63× magnification (Scale bars: 10 μM).CC BY · PubMed Central
Figure 8 HG, AGE, LPS, and TNFα treatment resulted in different intracellular distribution of β-catenin in HREC AJs. Representative confocal images of HREC monolayers subjected to 24 h treatment with TNFα (10 ng/mL), LPS (0.1 μg/mL), AGE (50 μg/mL), HG (30 mM), TCBN (10 μM), HG + TCBN, and AGE + TCBN showing changes in the intracellular distribution of β-catenin compared to PBS control. Images were taken using an LSM confocal microscope at 63× magnification (Scale bars: 10 μM).
Figure 8 HG, AGE, LPS, and TNFα treatment resulted in different intracellular distribution of β-catenin in HREC AJs. Representative confocal images of HREC monolayers subjected to 24 h treatment with TNFα (10 ng/mL), LPS (0.1 μg/mL), AGE (50 μg/mL), HG (30 mM), TCBN (10 μM), HG + TCBN, and AGE + TCBN showing changes in the intracellular distribution of β-catenin compared to PBS control. Images were taken using an LSM confocal microscope at 63× magnification (Scale bars: 10 μM).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

See all 15

Metadata

Authors
Rudraraju, M., Narayanan, S. P., & Somanath, P. R.
Affiliations
University of Georgia (US)
Corresponding author
  • Narayanan, S. Priya
  • Somanath, Payaningal R.
Venue
Life
Publisher
MDPI AG
Published
2021-12-27
Volume
12
Issue
1
Pages
33
ISSN
2075-1729 (ISSN-L)
OpenAlex
W4200529658
Cited by
15
References
75
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 6
FWCI
1.79
Type
journal article
Language
en
Open access
Locations
  • Life (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Eye Institute (R01EY028569)
  • National Center for Advancing Translational Sciences (UL1TR002378)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
blood-retinal barrier, retinal endothelial cells, diabetic retinopathy, uveitis, high glucose, advanced glycation end products, lipopolysaccharide, TNF-α, claudin-5, VE-cadherin, β-catenin, cell junctions, Akt signaling, p38 MAPK, barrier permeability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Distinct Mechanisms of Human Retinal Endothelial Barrier Modulation In Vitro by Mediators of Diabetes and Uveitis. https://app.cochat.ai/papers/10.3390/life12010033
The paper
Rudraraju, M., Narayanan, S. P., & Somanath, P. R. (2021). Distinct Mechanisms of Human Retinal Endothelial Barrier Modulation In Vitro by Mediators of Diabetes and Uveitis. Life. https://doi.org/10.3390/life12010033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.